

Please amend claim 1 as follows:

1. (once amended) [A]In a method of administering a gravity segregating dispersion to a subject by continuous infusion, [wherein said dispersion is controllably delivered]the improvement comprising controllably delivering said dispersion from an upper or lower extremity of an essentially vertically positioned delivery vessel and thereafter [is admixed]admixing with a flushing medium prior to administration to the subject.

Please amend claim 2 as follows:

2. (once amended) [A]The method [as claimed in]of claim 1 wherein said delivery vessel comprises a syringe.

Please amend claim 3 as follows:

3. (once amended) [A]The method [as claimed in]of claim 2 wherein delivery of said dispersion from said syringe is controlled by a syringe driver.

Please amend claim 4 as follows:

4. (once amended) [A]The method [as claimed in any of the preceding claims]of claim 1 wherein said dispersion is a gas-containing contrast agent.

Please amend claim 5 as follows:

5. (once amended) [A]The method [as claimed in]of claim 4 wherein said gas comprises sulphur hexafluoride or a perfluorinated low molecular weight hydrocarbon.

Please amend claim 6 as follows:

6. (once amended) [A]The method [as claimed in]of claim 5 wherein said perfluorinated hydrocarbon is perfluoropropane or perfluorobutane.

Please amend claim 7 as follows:

7. (once amended) [A]The method [as claimed in any of claims 4 to 6]of claim 4 wherein said gas is present as albumin-stabilised microbubbles.

Please amend claim 8 as follows:

8. (once amended) [A]The method [as claimed in any of claims 4 to 6]of claim 4 wherein said gas is present as phospholipid-stabilised microbubbles.

208020 " 505 1505 1007 2007

Please amend claim 9 as follows:

9. (once amended) [A]The method [as claimed in]of claim 8 wherein said phospholipid predominantly comprises phosphatidylserine.

Please amend claim 10 as follows:

10. (once amended) [A]The method [as claimed in any of claims 4 to 9]of claim 4 wherein the delivery vessel comprises a syringe positioned for upward delivery of said contrast agent.

Please amend claim 11 as follows:

11. (once amended) [A]The method [as claimed in any of the preceding claims]of claim 1 wherein said flushing medium is normal saline.

Please amend claim 12 as follows:

12. (once amended) [A]The method [as claimed in any of the preceding claims]of claim 1 wherein the admixed dispersion and flushing medium are administered by injection.

Please amend claim 13 as follows:

13. (once amended) [Apparatus]An apparatus for use in administration of a gravity segregating dispersion by continuous infusion, said apparatus comprising:
- (i) a delivery device adapted to receive a dispersion-containing delivery vessel in an essentially vertical position and controllably to expel dispersion from an upper or lower extremity of said vessel;
  - (ii) mixing means adapted to effect admixture of said expelled dispersion with a flushing medium; and
  - (iii) conduit means adapted to conduct said admixed dispersion and flushing medium to an administration device.

Please amend claim 14 as follows:

14. (once amended) [Apparatus as claimed in]The apparatus of claim 13 wherein said delivery device is a syringe driver adapted to receive an essentially vertically positioned syringe.

Please amend claim 15 as follows:

15. (once amended) [Apparatus as claimed in claim 13 or claim 14]The apparatus of claim 13 wherein said mixing means comprise a three way connector or tap

adapted to connect said delivery vessel and a source of flushing medium to said conduit means.

· Please amend claim 16 as follows:

16. (once amended) [Apparatus as claimed in any of claims 13 to 15] The apparatus of claim 13 which further comprises flow rate controlling means for controlling the rate of flow of said flushing medium.

Please amend claim 17 as follows:

17. (once amended) [Apparatus as claimed in any of claims 13 to 16] The apparatus of claim 13 which further comprises means for inverting the position of said delivery vessel.

---

### Remarks

Applicants have amended the specification to cross reference the parent application which is a PCT application designating the United States. Applicants have also amended the specification to add the required headings and move the text to be in the required order.

*ab*  
Applicants have cancelled claim 18, without prejudice. Applicants have amended claims 1-17 to more fully conform with U.S. practice. A version of the claims marked up